You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
亿胜生物科技(01061.HK)中期纯利增长31%至1.3亿港元
格隆汇 08-12 20:43

格隆汇8月12日丨亿胜生物科技(01061.HK)公布中期业绩,截至2019年6月30日止6个月,公司实现营业额5.82亿港元,同比增长3.64%;毛利4.69亿港元,同比增长2.06%;公司拥有人应占盈利1.3亿港元,同比增长31%;基本每股盈利22.39港仙 ;拟派发中期股息每股0.035港元。

公告表示,集团的收益主要来自中国业务,并以人民币计值。由于回顾期内人民币贬值,以港元计算的营业额受损约6.7%。人民币贬值及中国医疗保健系统政策的变化(包括两票制)对集团于期内的营业额直接产生了负面影响,导致较去年同期略增3.6%至约5.82亿港元,否则将较去年同期达致两位数的增长。

尽管营业额略增,但集团录得税后正面溢利约1.296亿港元,较去年同期增加31.0%。佳绩体现了其自2018年第四季度以来积极采取的销售及营销组织的有效内部改革及策略。

期内,集团于公开市场上出售部分其于MeiraGTx Holdings plc (股份代号:MGTX(纳斯达克))的投资,已实现收益净额约1800万港元。有关收益录入其他全面收益而非损益中。于2019年6月30日,所持剩余投资市值约为2680万港元。此乃自增进计划项下其投资组合中首次撤资。眼科及外科产品业务的营业额贡献分别为43.0%及57.0%。 

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account